10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Q3 revenue was $151.7 million, falling short of the $158.8 million analyst estimate. The company lowered its full-year 2024 revenue forecast to $595-605 million. Net loss narrowed to $35.8 million ...

Explore 10x Genomics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TXG. Life Science Company 10x Genomics Struggles With Profitability, Analyst Says ...

"This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal ...